ABE8e-V106W nSPRY mRNA, RG, 20 µg
ABE8e-V106W nSPRY mRNA from Aldevron is an in vitro–transcribed messenger RNA encoding the ABE8e adenine base editor carrying the V106W substitution in the TadA-8e deaminase domain, fused to the SpRY Cas9 nickase (nSPRY), an engineered near-PAMless Streptococcus pyogenes Cas9 variant that recognizes NRN PAM sequences. Guided by a single guide RNA, the editor converts adenine to guanine (A→G) within the canonical ABE8e editing window at target sites adjacent to an NRN PAM.
Base editing enables targeted nucleotide conversion without creating double-strand DNA breaks or requiring donor DNA templates.
Supplied at research grade for research use only.
Performance Highlights
- Enable A-to-G genome edits without double-strand DNA breaks
- Achieve efficient A→G conversion across diverse cell types
- Provides an NRN PAM compatible base editing option
Product Data
Base conversion efficiency across various immortal and primary cell lines

Figure 1: Target adenine editing efficiency across cell types for ABE8e-Cas variant combinations. Target adenine conversion at the indicated genomic loci was measured in HEK293, iPSC, K562, and primary T cells using ABE8e editors paired with nCas9, nSpG, or nSPRY. Data from ABE8e-WT and ABE8e-V106W were combined due to comparable on-target editing efficiencies and are presented as mean ± SEM (N = 6 biological replicates; 3 WT and 3 V106W). Cells were nucleofected using the Lonza nucleofection system with 1,000ng of base editor mRNA in HEK293, K562, and primary T cells or 500ng in iPSCs. gRNA was delivered at 2 µM in HEK293, K562, and iPSCs and 4 µM in primary T cells. High levels of target base conversion were observed across diverse cell types and Cas variants.
Visit the Base Editing mRNA product page to learn more.
If you need to speak to an expert, please fill in the contact us form and a member of our team will reach out to you.